Pharmathen: Sold to private equity Partners Group

BC Partners announced the sale of the majority stake in Pharmathen to the international private equity firm Partners Group. The transaction values ​​the company at 1.6 billion euros.

Pharmathen was founded in 1969 and was acquired by BC Partners in 2015 for 475 million euros and is now the leading European company in the field of drug administration technology, the announcement said.

With a highly diversified business model and strong management team, the company specializes in the development of "extended release" technologies, with top R&D capabilities, serving a blue-chip customer portfolio in nearly 100 countries worldwide.

"Owned by BC Partners, Pharmathen has grown into a technology-driven company leading a highly attractive industry, with strong and sustainable organic EBITDA growth of 16% on a weighted annual average over the last 5 years. The company is a world leader in the field of extended release compound injection products ("LAI"), while at the same time it has created a technology platform for prolonged release treatments ("LATT") that will fuel its growth for many years. "With a highly diversified product, customer and geographic base, Pharmathen is in a strong position to grow further, particularly in the US market, under the guidance of the Partners Group."

Mr. Nikos Stathopoulos, Partner and Head of BC Partners said: "At Pharmathen, we saw an opportunity to make a significant investment in a high quality business to accelerate its organic growth and develop the company into a global leader. During the period of our ownership, we invested more than € 250 million in Research and Development and in new FDA approved production facilities, we almost doubled the number of employees and implemented projects that really...